Published in Clin Sci on October 01, 1969
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Resistance to -adrenoceptor stimulants (a possible explanation for the rise in ashtma deaths). Br J Pharmacol (1971) 6.11
Prognosis of treated hypertension. Changes in life expectancy and causes of death between 1952 and 1967. Q J Med (1970) 3.71
Pharmacokinetics of inhaled substances. Postgrad Med J (1975) 3.52
Isoprenaline resistance and the use of pressurised aerosols in asthma. Lancet (1968) 3.33
Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther (1976) 3.13
Assessment of antipyrine kinetics by measurement in saliva. Br J Clin Pharmacol (1976) 2.78
Blood concentrations in man of fluorinated hydrocarbons after inhalation of pressurised aerosols. Lancet (1970) 2.48
Incidence of a positive direct coombs test in patients on alpha-methyldopa. Lancet (1966) 2.44
The fate of isoprenaline administered by pressurized aerosols. Br J Pharmacol (1970) 2.43
Drugs and the liver. Clin Pharmacol Ther (1998) 2.23
Positive direct Coombs tests and antinuclear factor in patients treated with methyldopa. Lancet (1967) 2.22
Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. Br J Clin Pharmacol (1978) 2.14
Antidepressants and heart disease. Br Med J (Clin Res Ed) (1984) 2.14
Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine). Clin Sci (1971) 2.11
The metabolic fate of DL(7-3H)isoprenaline in man and dog. Biochem J (1969) 2.06
Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline. Lancet (1977) 2.01
An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. Contraception (1979) 1.97
Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol (1989) 1.97
Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther (1977) 1.91
Hypertension and hyperuricaemia. Lancet (1966) 1.86
Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest (1974) 1.85
Dose-dependent enzyme induction. Clin Pharmacol Ther (1973) 1.84
Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol (1984) 1.82
Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol (1981) 1.81
May mothers given warfarin breast-feed their infants? Br Med J (1977) 1.80
Clinical implications of enzyme induction. Ann N Y Acad Sci (1971) 1.76
Changes in plasma -glutamyl transpeptidase activity associated with alterations in drug metabolism in man. Br Med J (1973) 1.76
Mixed function oxidase activity in microsomal fractions of human liver biopsy specimens [proceedings]. Br J Clin Pharmacol (1978) 1.75
Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet (1987) 1.70
Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol (1980) 1.69
Changes in liver blood flow during enzyme induction. Biochem Pharmacol (1971) 1.65
Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet (1983) 1.64
The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol (1987) 1.63
Kinetics of warfarin absorption in man. Clin Pharmacol Ther (1974) 1.63
Interindividual differences in rates of drug oxidation in man. Drug Metab Dispos (1974) 1.63
Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet (1990) 1.63
The fate of ethyltin and diethyltin derivatives in the rat. Biochem J (1967) 1.62
Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet (1966) 1.61
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther (1974) 1.61
Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol (1988) 1.56
Clinical pharmacology and therapeutics in undergraduate medical education in the UK: current status. Br J Clin Pharmacol (1994) 1.53
Treating mild hypertension. Br Med J (Clin Res Ed) (1985) 1.49
CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res (1994) 1.49
The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol (1987) 1.49
Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol (1981) 1.47
Wholesale hepatocytic differentiation in the rat from ductular oval cells, the progeny of biliary stem cells. J Hepatol (1997) 1.47
The effect of phenobarbitone-induction on vitamin D metabolism. Clin Sci (1972) 1.46
Postgraduate education in therapeutics: experience in Merseyside. Br Med J (1978) 1.44
Hypertension in the young. Q J Med (1967) 1.42
The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Clin Pharmacol (1980) 1.40
The interaction of antibiotics with synthetic steroids in the rat [proceedings]. Br J Pharmacol (1978) 1.40
Typhoid Carriers, with an account of Two Institution Outbreaks traced to the same "Carrier.". Proc R Soc Med (1908) 1.39
Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol (1990) 1.38
Metabolism of isoprenaline in dog and man. Br J Pharmacol (1972) 1.38
Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs (1981) 1.36
The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol (1990) 1.34
Metabolism of isoprenaline after aerosol and direct intrabronchial administration in man and dog. Br J Pharmacol (1974) 1.32
Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br J Clin Pharmacol (1981) 1.32
Regulatory challenges, reimbursement, and risk-benefit assessment. Clin Pharmacol Ther (2010) 1.32
Determination of primaquine in biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr (1984) 1.30
Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol (1983) 1.29
A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol (1988) 1.28
Immediate decrease by hydrocortisone of the plasma half-life of antipyrine. Br J Pharmacol (1973) 1.28
Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol (1985) 1.27
Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol (1986) 1.25
Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS (1994) 1.25
The effects of food on drug bioavailability. Br J Clin Pharmacol (1989) 1.25
Fluorescence studies on some hydroxypyridines including compounds of the vitamin B6 group. Biochem J (1966) 1.23
Methyldopa and haemolytic anaemia. Lancet (1966) 1.21
Nucleosomes bind to cell surface proteoglycans. J Biol Chem (1999) 1.20
Pharmacokinetics of metoclopramide. Lancet (1979) 1.20
Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man. Ann N Y Acad Sci (1971) 1.20
Species and sex differences in electron transport systems in liver microsomes and their relationship to ethylmorphine demethylation. Life Sci (1969) 1.20
The fate of inhaled terbutaline. Eur J Respir Dis Suppl (1984) 1.20
The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. Clin Pharmacol Ther (1978) 1.18
Concentration effect studies with oral metoclopramide. Br J Clin Pharmacol (1979) 1.18
High-performance liquid chromatographic analysis of amodiaquine in human plasma. J Chromatogr (1985) 1.17
Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man. Clin Sci Mol Med (1977) 1.17
Mechanisms of cell death. Arch Toxicol (1991) 1.17
Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension (1988) 1.17
Contribution of the liver to overall elimination of propranolol. J Pharmacokinet Biopharm (1976) 1.16
Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol (1977) 1.16
The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats. Life Sci II (1972) 1.16
Quantitative gas-liquid chromatographic method for the determination of indomethacin in biological fluids. J Chromatogr (1978) 1.14
Effect of chloroquine and primaquine on antipyrine metabolism. Br J Clin Pharmacol (1983) 1.13
The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol (1983) 1.13
Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro. Eur J Clin Pharmacol (1981) 1.12
Metabolism of isoprenaline in the intestine. J Pharm Pharmacol (1974) 1.12